JIANJUNGAOJIANJUN GAO9668GAO, JIANJUNAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1155 Pressler StHouston77030-3721TXAuthorship 1690171Authorship 1700944Authorship 1717171Authorship 1779822Authorship 187626110898490Gao JJ, Filla MB, Lorsbach RB, Pace JL, Crespo A, Russell SW, Murphy WJEuropean journal of immunologyProlonged exposure of mouse macrophages to IFN-beta suppresses transcription of the inducible nitric oxide synthase gene: altered availability of transcription factor Stat1alpha. Eur J Immunol. 2000 Jun; 30(6):1551-61.Eur J Immunol2000-06-01T00:00:002000Prolonged exposure of mouse macrophages to IFN-beta suppresses transcription of the inducible nitric oxide synthase gene: altered availability of transcription factor Stat1alpha.11359654Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, Dileepan KNJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine ResearchInterleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res. 2001 Apr; 21(4):231-40.J Interferon Cytokine Res2001-04-01T00:00:002001Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha.12935354Gao JJ, Diesl V, Wittmann T, Morrison DC, Ryan JL, Vogel SN, Follettie MTJournal of endotoxin researchBacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages. J Endotoxin Res. 2003; 9(4):237-43.J Endotoxin Res2003-01-01T00:00:002003Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages.16721267Shen J, Gao JJ, Zhang G, Tan X, Morrison DC, Papasian C, Vogel SN, Qureshi NShock (Augusta, Ga.)Proteasome-mediated regulation of CpG DNA- and peptidoglycan-induced cytokines, inflammatory genes, and mitogen-activated protein kinase activation. Shock. 2006 Jun; 25(6):594-9.Shock2006-06-01T00:00:002006Proteasome-mediated regulation of CpG DNA- and peptidoglycan-induced cytokines, inflammatory genes, and mitogen-activated protein kinase activation.20160661Gao JJ, Shen J, Kolbert C, Raghavakaimal S, Papasian CJ, Qureshi AA, Vogel SN, Morrison DC, Qureshi NShock (Augusta, Ga.)The proteasome regulates bacterial CpG DNA-induced signaling pathways in murine macrophages. Shock. 2010 Oct; 34(4):390-401.Shock2010-10-01T00:00:002010The proteasome regulates bacterial CpG DNA-induced signaling pathways in murine macrophages.Genitourinary Medical OncologyMD AndersonARLENE ODELIASIEFKER-RADTKEARLENE ODELIA SIEFKER-RADTKE8840SIEFKER-RADTKE, ARLENE ODELIAAssociate ProfessorASHISHKAMATASHISH KAMAT8961KAMAT, ASHISHProfessorPADMANEESHARMAPADMANEE SHARMA9187SHARMA, PADMANEEProfessor2.56050.00444281343research areas3.827840.0338652125coauthor of203.74114.995560similar to1190selected publicationsNIZAR MTANNIRNIZAR M TANNIR8865TANNIR, NIZAR MProfessorSURENAMATINSURENA MATIN9030MATIN, SURENAProfessorCOLIN PDINNEYCOLIN P DINNEY8624DINNEY, COLIN PProfessorAuthorship 2166961Authorship 2297181Authorship 232309110510342Gao JJ, Zuvanich EG, Xue Q, Horn DL, Silverstein R, Morrison DCJournal of immunology (Baltimore, Md. : 1950)Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol. 1999 Oct 15; 163(8):4095-9.J Immunol1999-10-15T00:00:001999Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages.20805455Gao JJ, Maricque BB, Morse MD, Huang W, McNeel DGJournal of clinical oncology : official journal of the American Society of Clinical OncologyIdentification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. J Clin Oncol. 2010 Nov 20; 28(33):e680-3.J Clin Oncol2010-08-30T00:00:002010Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease.23031830Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu PTrends in immunologyAdvances in the development of cancer immunotherapies. Trends Immunol. 2013 Feb; 34(2):90-8.Trends Immunol2012-09-30T00:00:002012Advances in the development of cancer immunotherapies.Authorship 2397491Authorship 2414731Authorship 2419782Authorship 2434223Authorship 2452592Authorship 25848138995425Gao J, Morrison DC, Parmely TJ, Russell SW, Murphy WJThe Journal of biological chemistryAn interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem. 1997 Jan 10; 272(2):1226-30.J Biol Chem1997-01-10T00:00:001997An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide.9794412Gao JJ, Filla MB, Fultz MJ, Vogel SN, Russell SW, Murphy WJJournal of immunology (Baltimore, Md. : 1950)Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene. J Immunol. 1998 Nov 01; 161(9):4803-10.J Immunol1998-11-01T00:00:001998Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene.10600009Chu W, Gao J, Murphy WJ, Hunt JSHuman immunologyA candidate interferon-gamma activated site (GAS element) in the HLA-G promoter does not bind nuclear proteins. Hum Immunol. 1999 Nov; 60(11):1113-8.Hum Immunol1999-11-01T00:00:001999A candidate interferon-gamma activated site (GAS element) in the HLA-G promoter does not bind nuclear proteins.12438335Papasian CJ, Silverstein R, Gao JJ, Bamberger DM, Morrison DCInfection and immunityAnomalous role of tumor necrosis factor alpha in experimental enterococcal infection. Infect Immun. 2002 Dec; 70(12):6628-37.Infect Immun2002-12-01T00:00:002002Anomalous role of tumor necrosis factor alpha in experimental enterococcal infection.14601445Lei MG, Gao JJ, Morrison DC, Qureshi NMissouri medicinePathogenesis of sepsis: current concepts and emerging therapies. Mo Med. 2003 Sep-Oct; 100(5):524-9.Mo Med2003-09-01T00:00:002003Pathogenesis of sepsis: current concepts and emerging therapies.23092383Liz?e G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu PAnnual review of medicineHarnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90.Annu Rev Med2012-10-22T00:00:002012Harnessing the power of the immune system to target cancer.Authorship 2648271Authorship 2717881612488506Gao JJ, Diesl V, Wittmann T, Morrison DC, Ryan JL, Vogel SN, Follettie MTJournal of leukocyte biologyRegulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol. 2002 Dec; 72(6):1234-45.J Leukoc Biol2002-12-01T00:00:002002Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide.23637996Gou HF, Li X, Qiu M, Cheng K, Li LH, Dong H, Chen Y, Tang Y, Gao F, Zhao F, Men HT, Ge J, Su JM, Xu F, Bi F, Gao JJ, Liu JYPloS oneEpidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One. 2013; 8(4):e62175.PLoS One2013-04-24T00:00:002013Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma.Authorship 276980111359845Gao JJ, Xue Q, Papasian CJ, Morrison DCJournal of immunology (Baltimore, Md. : 1950)Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol. 2001 Jun 01; 166(11):6855-60.J Immunol2001-06-01T00:00:002001Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism.Authorship 2919832Authorship 2926622Authorship 3037171925385470Jonasch E, Gao J, Rathmell WKBMJ (Clinical research ed.)Renal cell carcinoma. BMJ. 2014 Nov 10; 349:g4797.BMJ2014-11-10T00:00:002014Renal cell carcinoma.25498220Siefker-Radtke AO, Gao JThe Lancet. OncologyTowards effective adjuvant treatment for urothelial cancer. Lancet Oncol. 2015 Jan; 16(1):9-10.Lancet Oncol2014-12-11T00:00:002014Towards effective adjuvant treatment for urothelial cancer.26014097Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch ECancer immunology researchResistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.Cancer Immunol Res2015-05-26T00:00:002015Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.74Professor10Assistant Professor14Associate ProfessorAMISHI YOGESHSHAHAMISHI YOGESH SHAH12370SHAH, AMISHI YOGESHAssistant ProfessorAuthorship 841210Authorship 847054Authorship 850700Authorship 855572Authorship 856310Authorship 856366Authorship 857055Authorship 859107Authorship 862886Authorship 868061Journal for ImmunoTherapy of CancerAcute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer. 4.Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibodyCancer Journal (United States)The state of immune checkpoint inhibition in urothelial carcinoma current evidence and future areas of exploration. Cancer Journal (United States). 22:96-100.The state of immune checkpoint inhibition in urothelial carcinoma current evidence and future areas of explorationCellLoss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 167:397-404.e9.Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyOncogeneReview of immune-related adverse events in prostate cancer patients treated with ipilimumab. Oncogene. Review of immune-related adverse events in prostate cancer patients treated with ipilimumabFASEB JournalLPS stimulates statla phosphorylation in mouse macrophages without autocrine feedback by interferon-γ. FASEB Journal. 10.LPS stimulates statla phosphorylation in mouse macrophages without autocrine feedback by interferon-γCancer immunology researchResistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer immunology research. 3:1017-1029.Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinomaBJU InternationalManagement and outcomes of patients with renal medullary carcinoma. BJU International. Management and outcomes of patients with renal medullary carcinomaBMJ Case ReportsSystemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Reports. 2016.Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibitionProceedings of the National Academy of Sciences of the United States of AmericaClonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. 113:11919-11924.Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesNature CommunicationsInterdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7.Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapytrue1ProfessorProfessorD014571Disorders621880.824583Urologic NeoplasmsD008264Anatomy61113050.615055MacrophagesD000911Chemicals & Drugs99043510.391387Antibodies, MonoclonalD001749Disorders29623300.398698Urinary Bladder NeoplasmsD002295Disorders1579530.582542Carcinoma, Transitional CellAuthorship 9060211Authorship 9069583Authorship 9093899Authorship 9100302Authorship 9116303Authorship 9125817Authorship 9128363Authorship 9165027Authorship 9190912Authorship 9197283Authorship 9212961Authorship 9232863Authorship 9281752Authorship 93325616Authorship 9335951627498556Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma PNature communicationsInterdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.Nat Commun2016-08-08T00:00:002016Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy.27111904Campbell MT, Siefker-Radtke AO, Gao JCancer journal (Sudbury, Mass.)The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. Cancer J. 2016 Mar-Apr; 22(2):96-100.Cancer J2016-03-01T00:00:002016The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.27330809Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma PJournal for immunotherapy of cancerAcute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016; 4:36.J Immunother Cancer2016-06-21T00:00:002016Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.27667683Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma PCellLoss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.Cell2016-09-22T00:00:002016Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.27797838Kim C, Gao J, Shannon VR, Siefker-Radtke ABMJ case reportsSystemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep. 2016 Oct 26; 2016.BMJ Case Rep2016-10-26T00:00:002016Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition.27698113Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma PProceedings of the National Academy of Sciences of the United States of AmericaClonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.Proc Natl Acad Sci U S A2016-10-03T00:00:002016Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.27860149Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NMBJU internationalManagement and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.BJU Int2016-12-09T00:00:002016Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.28346412Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma PNature medicineVISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.Nat Med2017-03-27T00:00:002017VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.28733428Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang JCancer discoveryTCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.Cancer Discov2017-07-21T00:00:002017TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.28877627Shah AY, Gao J, Siefker-Radtke AOImmunotherapyFive new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy. 2017 09; 9(10):781-784.Immunotherapy2017-09-01T00:00:002017Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer.29553950Tabayoyong W, Gao JCurrent opinion in oncologyThe emerging role of immunotherapy in advanced urothelial cancers. Curr Opin Oncol. 2018 05; 30(3):172-180.Curr Opin Oncol2018-05-01T00:00:002018The emerging role of immunotherapy in advanced urothelial cancers.29650132Tabayoyong W, Li R, Gao J, Kamat AThe Urologic clinics of North AmericaOptimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urol Clin North Am. 2018 May; 45(2):155-167.Urol Clin North Am2018-02-21T00:00:002018Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.30169584Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang YInflammatory bowel diseasesCan Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflamm Bowel Dis. 2019 01 10; 25(2):385-393.Inflamm Bowel Dis2019-01-10T00:00:002019Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?30420754Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RRNature medicineFecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.Nat Med2018-11-12T00:00:002018Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.30479380Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RRNature medicineAuthor Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2019 Jan; 25(1):188.Nat Med2019-01-01T00:00:002019Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.UrologyDepartment of UrologyUrologyBaylor College of MedicineSETHLERNERSETH LERNER29.70990600000000-95.402830000000002886LERNER, SETHProfessorAuthorship 9465402031067463Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak BCell reportsDysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.Cell Rep2019-05-07T00:00:002019Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer.Authorship 9482831731163011Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang YJournal of clinical oncology : official journal of the American Society of Clinical OncologyResumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019 10 20; 37(30):2738-2745.J Clin Oncol2019-06-04T00:00:002019Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.31466995Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma PCancer immunology researchBlockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.Cancer Immunol Res2019-08-29T00:00:002019Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.Authorship 95675914Authorship 957228231611368Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma PProceedings of the National Academy of Sciences of the United States of AmericaAutoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.Proc Natl Acad Sci U S A2019-10-14T00:00:002019Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.Authorship 975867331942075Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Saut?s-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JANatureB cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.Nature2020-01-15T00:00:002020B cells and tertiary lymphoid structures promote immunotherapy response.Authorship 980284532209822Alhalabi O, Campbell M, Shah A, Siefker-Radtke A, Gao JCurrent opinion in oncologyEmerging treatments in advanced urothelial cancer. Curr Opin Oncol. 2020 05; 32(3):232-239.Curr Opin Oncol2020-05-01T00:00:002020Emerging treatments in advanced urothelial cancer.32359397Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pili? PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NMCancer cellComprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.Cancer Cell2020-04-30T00:00:002020Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.Authorship 9889716Authorship 9915141532521509Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, Logothetis C, Siefker-Radtke A, Kamat A, Dinney C, Theodorescu D, Kimmel M, Wei P, Guo CC, Weinstein JN, McConkey DJ, Czerniak BiScienceUrothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.iScience2020-05-27T00:00:002020Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer.Authorship 9920341432546765Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, Lee JG, Cogdell D, Zhang M, Yang G, Dadhania V, Choi W, Wei P, Gao J, Theodorescu D, Logothetis C, Dinney C, Kimmel M, Weinstein JN, McConkey DJ, Czerniak BScientific reportsAssessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.Sci Rep2020-06-16T00:00:002020Assessment of Luminal and Basal Phenotypes in Bladder Cancer.Authorship 998978232947310Hasanov E, Gao J, Tannir NMCancer journal (Sudbury, Mass.)The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results. Cancer J. 2020 Sep/Oct; 26(5):419-431.Cancer J2020-09-01T00:00:002020The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results.Authorship 1002712133046869Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma PNature medicineNeoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.Nat Med2020-10-12T00:00:002020Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.Authorship 10050226Authorship 1005288933210440Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AMBJU internationalThe obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin. BJU Int. 2021 07; 128(1):65-71.BJU Int2020-12-05T00:00:002020The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin.33187886Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NMUrologic oncologyOutcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.Urol Oncol2020-11-10T00:00:002020Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.Authorship 10069362033323389Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah VMolecular cancer research : MCRMolecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402.Mol Cancer Res2020-12-15T00:00:002020Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes.Authorship 1007693333356674Msaouel P, Genovese G, Gao J, Sen S, Tannir NMExpert opinion on therapeutic targetsTAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin Ther Targets. 2021 02; 25(2):141-151.Expert Opin Ther Targets2020-12-31T00:00:002020TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?Authorship 1014077933739450Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NMInternational journal of cancerOutcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021 07 15; 149(2):387-393.Int J Cancer2021-03-24T00:00:002021Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.Authorship 1014313733747934Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MTFrontiers in oncologyCase Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol. 2021; 11:621591.Front Oncol2021-03-04T00:00:002021Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction.Authorship 10150336Authorship 1015846633818541Andreev-Drakhlin AY, Egoryan G, Shah AY, Msaouel P, Alhalabi O, Gao JCurrent opinion in oncologyThe evolving treatment landscape of advanced urothelial carcinoma. Curr Opin Oncol. 2021 05 01; 33(3):221-230.Curr Opin Oncol2021-05-01T00:00:002021The evolving treatment landscape of advanced urothelial carcinoma.33811120Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JPCancer discoveryThe Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 04; 11(4):838-857.Cancer Discov2021-04-01T00:00:002021The Next Decade of Immune Checkpoint Therapy.Authorship 1024117834184926Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AMThe Journal of urologyProgression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.J Urol2021-06-29T00:00:002021Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.Authorship 1026469634326169Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir NJournal for immunotherapy of cancerDurable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).J Immunother Cancer2021-07-01T00:00:002021Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.Authorship 10269232134362693Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah VClinical genitourinary cancerValidation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24.Clin Genitourin Cancer2021-07-12T00:00:002021Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.Authorship 1027410834372685Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AMThe Journal of urologyReply by Authors. J Urol. 2021 11; 206(5):1267.J Urol2021-08-10T00:00:002021Reply by Authors.Authorship 1028736634459906Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis CJAMA network openEvaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998.JAMA Netw Open2021-08-02T00:00:002021Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.Authorship 10302533134556668Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang LNature communications9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.Nat Commun2021-09-23T00:00:0020219p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.Authorship 103372912Authorship 10342962834737281Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma PNature communicationsPilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.Nat Commun2021-11-04T00:00:002021Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.34789422Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao JEuropean urology oncologyIntegrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.Eur Urol Oncol2021-11-14T00:00:002021Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer.Authorship 10400601135039231Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MTClinical genitourinary cancerFive and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.Clin Genitourin Cancer2021-12-24T00:00:002021Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma.Authorship 104337445Authorship 10442117Authorship 10444448Authorship 10445721035379845Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao JNature communicationsMTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797.Nat Commun2022-04-04T00:00:002022MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.35442707Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NMScience translational medicineA phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.Sci Transl Med2022-04-20T00:00:002022A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.35467000Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CCAmerican journal of clinical pathologyDistinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.Am J Clin Pathol2022-08-04T00:00:002022Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.35475152Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AYBJUI compassMultimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44.BJUI Compass2021-10-11T00:00:002021Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.Authorship 10488151835747385Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y, Dinh KN, Majewski T, Zhang L, Cao S, Tian F, Yao H, Kus P, Chen H, Weinstein JN, Navai N, Dinney C, Gao J, Theodorescu D, Logothetis C, Guo CC, Wang W, McConkey D, Wei P, Kimmel M, Czerniak BiScienceThe origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104551.iScience2022-06-07T00:00:002022The origin of bladder cancer from mucosal field effects.Authorship 10547101035961847Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SFUrologic oncologyLongitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.Urol Oncol2022-08-10T00:00:002022Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.Authorship 10630001936724291Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hung MC, Curran MA, Calin GA, Ying H, Han L, Lin C, Yang LScience advancesTumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv. 2023 02 03; 9(5):eadd6995.Sci Adv2023-02-01T00:00:002023Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion.Authorship 1064790836863962Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel PEuropean urology focusCytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741.Eur Urol Focus2023-02-28T00:00:002023Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.Authorship 1066826636966497Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao JCurrent opinion in oncologyEvolving systemic management of urothelial cancers. Curr Opin Oncol. 2023 05 01; 35(3):186-199.Curr Opin Oncol2023-03-14T00:00:002023Evolving systemic management of urothelial cancers.Authorship 1070854637154098Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DEEndocrinologyStranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology. 2023 04 17; 164(6).Endocrinology2023-04-17T00:00:002023Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.Authorship 10729062337365326Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese GNature cancerInterferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer. 2023 07; 4(7):984-1000.Nat Cancer2023-06-26T00:00:002023Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.Authorship 1080913937833193Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AOEuropean urology oncologyComparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.Eur Urol Oncol2023-10-11T00:00:002023Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.Authorship 10832101237922370Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AMThe Journal of urologyLong-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255.J Urol2023-11-03T00:00:002023Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.Authorship 10836871038035767Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel PThe oncologistTreatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist. 2023 Nov 30.Oncologist2023-11-30T00:00:002023Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.Authorship 1085885638152395Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JVFrontiers in immunologyDistinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol. 2023; 14:1322818.Front Immunol2023-12-12T00:00:002023Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.Authorship 10890861438355560Amara CS, Kami Reddy KR, Yuntao Y, Chan YS, Piyarathna DWB, Dobrolecki LE, Shih DJH, Shi Z, Xu J, Huang S, Ellis MJ, Apolo AB, Ballester LY, Gao J, Hansel DE, Lotan Y, Hodges HC, Lerner SP, Creighton CJ, Sreekumar A, Zheng WJ, Msaouel P, Kavuri SM, Putluri NNature communicationsThe IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun. 2024 Feb 14; 15(1):1373.Nat Commun2024-02-14T00:00:002024The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.Authorship 1090509738478923Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NMThe oncologistEfficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist. 2024 Mar 13.Oncologist2024-03-13T00:00:002024Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor